Compare ADMA Biologics Inc (ADMA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Mesoblast Limited — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Mesoblast Limited trades at $17.03 (market cap $2.21B). The key difference: ADMA Biologics Inc and Mesoblast Limited are close in size by market cap, and Mesoblast Limited is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MESO | |
|---|---|---|
Market Cap | $2.22B | $2.21B |
Sector | Health | Technology |
52-Week High | $20.38 | $20.96 |
52-Week Low | $7.60 | $12.88 |
Enterprise Value | $2.29B | $2.21B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
